Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study
Fig 5
Representative cases of the G1 and G4 groups.
(A) The contrast-enhanced ultrasound showed the hyper-vascular tumor in the left lobe of the liver (upper, arrows). The mass showed a decrease of vascularity after combination treatment of sorafenib (SOR) and doxorubicin-loaded microbubble-albumin nanoparticle complex (DOX-MAC) (lower, arrows). (B) One of the G5 group showed the small hyper-vascular tumor in the left lobe of the liver (upper, arrows). The mass showed an increase of tumor volume with hyper-vascularity without any treatment (lower, arrows). (C) The number of brown-colored stained apoptotic cells on TUNEL staining (×400) was a subtle increase in the G1 group (upper, arrowheads) than the G5 group (lower, arrowheads) without statistical significance. (D) The number of brown-colored stained endothelial cells on CD31 staining (×200) decreased in the G1 group (upper, arrowheads) than the G5 group (lower, arrowheads).